An artist's illustration of monoclonal antibodies fighting coronavirus. For a treatment showing early promise, there hasn't been much pick up of monoclonal antibodies in COVID-19. (iStockphoto/Getty) ...

While common sense may suggest that antibodies that do not neutralize the SARS-CoV-2 virus are of little value, recent studies show they can still confer protection against infection.

Monoclonal antibodies were once the star of COVID-19 outpatient treatments. Since they first became available in 2020 – even before the first vaccines – more than 3.5 million infusions of the ...

Monoclonal antibodies offer hope for tackling antimicrobial resistance Date: September 16, 2024 Source: University of Cambridge Summary: Monoclonal antibodies -- treatments developed by cloning a ...

Notably, monoclonal antibodies that target highly conserved regions of the spike, such as the S2 region, or anti-ACE2 antibodies we have previously discussed could be possible combination options.

A Hamilton-based clinic that provides a new therapy aimed at keeping high-risk COVID-19 patients out of hospital is seeing "incredible results," according to the doctor leading it.

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...

This study is led by Dr. Hassan Aboul-Ella (Department of Microbiology, Faculty of Veterinary Medicine, Cairo University). Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a ...

Monoclonal antibodies are a key tool doctors use to treat severe COVID-19, and are particularly important for severely immunocompromised patients or people who cannot get vaccinated.